(Q33417472)

English

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

object named as

Damon R Reed

4

0 references

author name string

Sant P Chawla

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lee D Cranmer

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Brian A Van Tine

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott H Okuno

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

James E Butrynski

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Douglas R Adkins

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew E Hendifar

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stew Kroll

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kristen N Ganjoo

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

2 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

3299-3306

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Targeting hypoxic tumour cells to overcome metastasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Histology-driven chemotherapy of soft-tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Detection and characterization of tumor hypoxia using pO2 histography

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Exploiting tumour hypoxia in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Oxygen dependence of the cytotoxicity of the enediyne anti-tumour antibiotic esperamicin A1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

28 July 2018

Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Stud

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4588714

31 October 2018

Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment oxygenation profiles of human soft tissue sarcomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/25185097

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.54.3660

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417472&oldid=1536312736"